Format

Send to

Choose Destination
Cancer. 2016 Jun 15;122(12):1853-60. doi: 10.1002/cncr.29962. Epub 2016 Mar 28.

Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base.

Author information

1
Division of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, Connecticut.
2
Division of Endocrine Surgery, Department of Surgery, Duke University School of Medicine, Durham, North Carolina.
3
Duke Clinical Research Institute, Durham, North Carolina.
4
Duke Cancer Institute, Durham, North Carolina.
5
Yale Cancer Center, New Haven, Connecticut.
6
Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
7
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
8
Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

Abstract

BACKGROUND:

The current study was performed to characterize trends and survival outcomes for chemotherapy in the definitive and adjuvant treatment of hypopharyngeal cancer in the United States.

METHODS:

A total of 16,248 adult patients diagnosed with primary hypopharyngeal cancer without distant metastases between 1998 and 2011 were identified in the National Cancer Data Base. The association between treatment modality and overall survival was analyzed using Kaplan-Meier survival curves and 5-year survival rates. A multivariate Cox regression analysis was performed on a subset of 3357 cases to determine the treatment modalities that predict improved survival when controlling for demographic and clinical factors.

RESULTS:

There was a significant increase in the use of chemotherapy with radiotherapy both as definitive treatment (P<.001) and as adjuvant chemoradiotherapy with surgery (P=.001). This was accompanied by a decrease in total laryngectomy/pharyngectomy rates (P<.001). Chemoradiotherapy was associated with improved 5-year survival compared with radiotherapy alone in the definitive setting (31.8% vs 25.2%; log rank P<.001). Similarly, in multivariateanalysis, definitive radiotherapy was found to be associated with compromised survival compared with definitive chemoradiotherapy (hazard ratio, 1.51; P<.001).

CONCLUSIONS:

Survival analysis revealed that overall 5-year survival rates were higher for chemoradiotherapy compared with radiotherapy alone in the definitive setting, but were comparable between surgery with chemoradiotherapy and surgery with radiotherapy. Cancer 2016;122:1853-60. © 2016 American Cancer Society.

KEYWORDS:

chemotherapy; head and neck cancer; hypopharyngeal cancer; hypopharynx; survival

PMID:
27019213
DOI:
10.1002/cncr.29962
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center